MedPath

Emmaus Medical, Inc.

Emmaus Medical, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2000-01-01
Employees
51
Market Cap
-
Website
http://www.emmausmedical.com

Clinical Trials

4

Active:0
Completed:4

Trial Phases

4 Phases

Phase 1:1
Phase 2:1
Phase 3:1
+1 more phases

Drug Approvals

1

FDA:1

Drug Approvals

Endari

Approval Date
Aug 19, 2022
FDA

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (25.0%)
Phase 2
1 (25.0%)
Phase 3
1 (25.0%)
Phase 4
1 (25.0%)

L-glutamine Treatment in Patients With Diverticulosis

Phase 1
Completed
Conditions
Diverticulosis, Colonic
Interventions
First Posted Date
2021-11-03
Last Posted Date
2023-02-16
Lead Sponsor
Emmaus Medical, Inc.
Target Recruit Count
9
Registration Number
NCT05106101
Locations
🇺🇸

The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States

🇺🇸

Ventura Clinical Trials, Ventura, California, United States

🇺🇸

Clinical Trials of Texas, Inc., San Antonio, Texas, United States

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

Phase 4
Completed
Conditions
Sickle Cell Disease
Pharmacokinetics
Interventions
First Posted Date
2020-12-24
Last Posted Date
2022-08-02
Lead Sponsor
Emmaus Medical, Inc.
Target Recruit Count
13
Registration Number
NCT04684381
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Phase 3
Completed
Conditions
Sickle Cell Anemia
Sickle ß0-Thalassemia
Interventions
Drug: Placebo
First Posted Date
2010-08-11
Last Posted Date
2020-08-19
Lead Sponsor
Emmaus Medical, Inc.
Target Recruit Count
230
Registration Number
NCT01179217
Locations
🇺🇸

University of South Alabama Medical Center, Mobile, Alabama, United States

🇺🇸

Phoenix Children's Hospital Center for Cancer and Blood Disorders, Phoenix, Arizona, United States

🇺🇸

Kaiser Permanente, Inglewood, California, United States

and more 28 locations

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Phase 2
Completed
Conditions
Thalassemia
Sickle Cell Anemia
Interventions
Drug: Placebo
First Posted Date
2005-08-02
Last Posted Date
2021-01-29
Lead Sponsor
Emmaus Medical, Inc.
Target Recruit Count
70
Registration Number
NCT00125788
Locations
🇺🇸

Kaiser Permanente, Bellflower, California, United States

🇺🇸

Harbor-UCLA Medical Center, Torrance, California, United States

🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.